The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering

Michelle L. O’Donoghue; Robert S. Rosenson; J. Antonio G. López; Norman E. Lepor; Seth J. Baum; Elmer Stout; Daniel Gaudet; Beat Knüsel; Julia Kuder; Sabina A. Murphy; Huei Wang; You Wu; Trupti Shah; Jingying Wang; Tomasz Wilmanski; Winnie Sohn; Helina Kassahun; Marc S. Sabatine

doi:10.1016/j.jacc.2024.05.058

Key Points

Circulating lipoprotein(a) levels decrease substantially following administration of olpasiran, which blocks the translation of apolipoprotein(a) mRNA.
Reductions exceeding 95 percent in circulating lipoprotein(a) occur with higher doses of olpasiran administered every 12 weeks during phase 2 evaluation.
Phase 2 findings highlight how targeted small interfering RNA therapy can suppress apolipoprotein(a) translation to yield durable clinical benefits.

Implication

Phase 2 trial reveals marked lipoprotein(a) lowering with olpasiran every 12 weeks, indicating sustained off-treatment efficacy.

Abstract

Olpasiran, a small interfering RNA (siRNA), blocks lipoprotein(a) (Lp(a)) production by preventing translation of apolipoprotein(a) mRNA. In phase 2, higher doses of olpasiran every 12 weeks (Q12W) reduced circulating Lp(a) by >95%.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

O’Donoghue et al. (2024) studied this question.

synapsesocial.com/papers/68e5dc44b6db643587571785 https://doi.org/10.1016/j.jacc.2024.05.058

View Full Paper

Ask AI

Bookmark

Share

The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering

Key Points

Implication

Abstract

Discussion

Cite This Study

The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Journal of the American College of Cardiology

Keep reading

More related papers

More from Journal of the American College of Cardiology